Rezultati pretrage - J.M. del Campo

  • Prikaz rezultata 1 – 9 od 9
Detaljiziraj rezultate
  1. 1
    Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

    Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy od Enriqueta Felip, J.M. del Campo, Diego Rubio, María Vidal, Rámón Colomer, Begoña Bermejo

    Izdano 1995
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  2. 2
    Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

    Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanc... od J.M. del Campo, A. Roszak, Mariusz Bidziński, Tudor–Eliade Ciuleanu, Thomas Högberg, Marek Z. Wojtukiewicz, Andrés Poveda, Karin Boman, Anneke M. Westermann, Claudia Lebedinsky

    Izdano 2009
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  3. 3
    A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

    A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck od Tanguy Y. Seiwert, Jérôme Fayette, Didier Cupissol, J.M. del Campo, Paul M. Clément, Ricardo Hitt, M. Degardin, W. Zhang, Alice Blackman, E. Ehrnrooth, Ezra E.W. Cohen

    Izdano 2014
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity

    Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity od Aleix Prat, Bárbara Adamo, Cheng Fan, Vicente Peg, María Vidal, Patricia Galván, Ana Vivancos, Paolo Nucíforo, Héctor G. Pálmer, Shaheenah Dawood, Jordi Rodón, Santiago Ramón y Cajal, J.M. del Campo, Enriqueta Felip, Josep Tabernero, Javier Cortés

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  5. 5
    Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

    Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck od J.M. del Campo, Ricardo Hitt, P. Sebastian, Carlos Carracedo, D. Lokanatha, Jean Bourhis, Stéphane Temam, Didier Cupissol, D. De Raucourt, N Maroudias, Chris Nutting, Natalie Compton, Dawn Midwinter, Laura E. Downie, Nigel Biswas–Baldwin, Iman El‐Hariry, Kevin J. Harrington

    Izdano 2011
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  6. 6
    Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer

    Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer od Andrés Poveda, J.M. del Campo, Isabelle Ray‐Coquard, J. Alexandre, Magali Provansal, Eva Maria Guerra Alía, Antonio Casado, Antonio González-Martı́n, Carmen Jiménez Fernández, Ignacio Rodríguez‐García, A. Soto, Carmen Kahatt, Carlos Fernández Teruel, Carlos M. Galmarini, Aitor Pérez de la Haza, Patrick Bohan, Dominique Berton-Rigaud

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  7. 7
    Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial

    Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 tr... od Paul M. Clément, Thomas Gauler, J.-P. Machiels, Robert I. Haddad, Jérôme Fayette, Lisa Licitra, Makoto Tahara, Ezra E.W. Cohen, Didier Cupissol, Juan J. Grau, J. Guigay, Francesco Caponigro, Gilberto de Castro, Luciano de Souza Viana, Ulrich Keilholz, J.M. del Campo, Xiuyu Julie Cong, E. Ehrnrooth, Jan B. Vermorken

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  8. 8
    Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

    Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer od Ezra E.W. Cohen, Lisa Licitra, Barbara Burtness, Jérôme Fayette, Thomas Gauler, Paul M. Clément, Juan J. Grau, J.M. del Campo, Audrey Mailliez, Robert I. Haddad, Jan B. Vermorken, Makoto Tahara, J. Guigay, Lionnel Geoffrois, Marco Merlano, Nicholas Dupuis, Nicole Krämer, Xiuyu Julie Cong, Neil Gibson, Flavio Solca, E. Ehrnrooth, J.-P. Machiels

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  9. 9
    Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

    Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck od Barbara Burtness, Robert I. Haddad, José Dinis, José Trigo, Tomoya Yokota, Luciano de Souza Viana, И. С. Романов, Jan B. Vermorken, Jean Bourhis, Makoto Tahara, José Getulio Martins Segalla, Amanda Psyrri, Irina A. Vasilevskaya, Chaitali Nangia, Manuel Chaves-Conde, Naomi Kiyota, Akihiro Homma, Petra Holečková, J.M. del Campo, Nirav Asarawala, Ulisses Ribaldo Nicolau, Daniel Rauch, Caroline Even, Bushi Wang, Neil Gibson, E. Ehrnrooth, Kevin J. Harrington, Ezra E.W. Cohen

    Izdano 2019
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: